Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Bristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to...

  • Thursday, August 2, 2012, 8:49 AM ET
    Bristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure, raising questions about the drug's potential and the $2.5B it paid earlier this year to buy the company that developed it. Companies that could benefit from BMY's woes: GILD +8.8%, IDIX +8.2% premarket.
Track new comments on this story

This news story has 2 comments:

  •  
    Don't forget ACHN it has the chance for a big rebound since it was being looked at the same time BMY bought.
    2 Aug 2012, 09:29 AM Reply Like
  •  
    BMY: For whatever it is worth. I only own a little over 500 shares, looks like down today but up until today 10.5% + dividend. Their new miracle product Yervoy just saved or extended my life. After 4 90 minute drips of the Immunoe Therapy, my Stage 4 Melanoma is totally gone. Not sure what impact this may make in the long term, but I am going to stay with them. Am I too emotionally attached?
    2 Aug 2012, 09:35 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »